CellCentric has completed an oversubscribed $220 million Series D financing led by Venrock Healthcare Capital Partners, with participation from new and existing investors. The proceeds will support clinical trials for multiple myeloma therapy inobrodib. These will include continued enrolment of the company’s Phase II DOMMINO-1 study and… Read More
AstraZeneca and Immunai have expanded their collaboration, extending a multi-year collaboration in oncology clinical development through 2027. Under the new deal, Immunai is eligible to receive up to $37.5 million over 2026-2027. It marks the third expansion of the partnership between the two companies, building on previous… Read More
Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion. Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market… Read More
UK biotech company Cytospire Therapeutics has closed a £61 million ($83 million) Series A financing round to advance T cell engagers, 4BIO Capital has announced. The venture capital firm led the financing round, with proceeds allowing Cytospire to advance its pipeline of first-in-class pan-gamma delta T cell engagers. The company’s lead programme,… Read More
Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline. The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund. … Read More
Techbio company Genomics has partnered with biotech company Greywolf Therapeutics to advance novel antigen modulation treatments to treat autoimmune diseases. Under the agreement, Genomics is set to curate and analyse large-scale genetic datasets to assess how variants of the ERAP (Endoplasmic Reticulum Aminopeptidases) enzymes influence disease risk across… Read More
EnteroBiotix has announced it has secured £19 million ($26 million) in financing to advance a treatment for irritable bowel syndrome. The biopharmaceutical company is set to use the investment to advance its lead candidate, EBX-102-02, a next-generation orally delivered full-spectrum investigational microbiome therapeutic. EBX-102-02 will be advanced into Phase… Read More
AstraZeneca’s investment U-turn shows the UK is “a global destination for life sciences investment”, the ABPI’s Chief Executive has said. Richard Torbett was speaking after AstraZeneca announced it would resume large-scale activity in the UK with a £300 million ($405 million) investment. The drugmaker had previously rolled back… Read More
Kurma Partners, a European healthcare venture capital firm, has announced the final closing of Biofund IV at €215 million. The new fund will support the discovery and development of disruptive therapeutic solutions for severe or incurable diseases. Building on the €160 million Biofund III, this… Read More
Aligos Therapeutics and Xiamen Amoytop Biotech have entered into an exclusive license agreement to develop and commercialise pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. Under the terms of the agreement, Aligos will receive an upfront milestone of $25 million and is eligible… Read More
UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. UCB will pay… Read More
Eli Lilly has reached an agreement to acquire Kelonia Therapeutics, a clinical-stage biotechnology company pioneering in vivo gene delivery, for up to $7 billion. Kelonia has developed a proprietary in vivo gene placement system (iGPS0) that uses specially engineered lentiviral-based particles designed to… Read More
Pharmaceutical companies Regeneron and Telix have announced a collaboration to develop and commercialise next generation radiopharmaceutical therapies. The collaboration will include multiple solid tumour targets from Regeneron’s portfolio of antibodies. The companies also aim to develop radio-diagnostics to support patient selection and treatment response assessment. The deal… Read More
Eli Lilly has signed a definitive agreement to acquire preclinical biotechnology company CrossBridge Bio for up to $300 million in cash, inclusive of an upfront payment and a subsequent milestone-dependent payment. CrossBridge Bio, a Houston-based biotechnology firm founded in 2023, is developing a new dual-payload ADC technology… Read More
Biotechnology companies Circio Holding and Acuitas Therapeutics have entered a technology evaluation agreement for an in vivo CAR-T cell therapy. As part of the agreement, Circio’s circVec circular RNA expression technology will be tested alongside Acuitas’ proprietary T-cell-targeted lipid nanoparticle (LNP) delivery system. The companies aim to assess whether Acuitas’ LNP technology can be deployed to deliver circVec for… Read More
Biotechnology company STORM Therapeutics has announced it has secured $56 million in a Series C financing to support its sarcoma treatment. The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. This extends to funding the company’s Phase II monotherapy study… Read More
